Industry Spotlight #2

Insights with Impact: Breaking the boundaries of CGP with MSK-IMPACT® powered with SOPHiA DDM™

Sunday, April 13 | 11:45 a.m.–12:15 p.m.

Hosted by: SOPHiA GENETICS

Dr. Hemad Yasaei, Head of Molecular Genomics, National Reference Laboratory (NRL), Abu Dhabi

Comprehensive genomic profiling (CGP) of solid tumors has become an essential tool in guiding precision medicine approaches. As cancer research advances, clinical laboratories require fast, scalable, and accurate CGP technologies to detect both known and emerging biomarkers with confidence. 

Through the decentralized and technology-agnostic SOPHiA DDM™ Platform, institutions worldwide can now benefit from MSK-IMPACT®, Memorial Sloan Kettering Cancer Center’s best-in-class CGP application. This innovative solution leverages matched tumor-normal sequencing to reveal variants of true somatic origin, delivering highly accurate research insights.   

Join Dr. Hemad Yasaei, Head of Molecular Genomics at National Reference Laboratory, UAE, as he shares his experience of: 

• The real-world challenges and successes of implementing an in-house CGP solution. 

• Analytical performance results, end-to-end workflow efficiency, and ease of use of MSK-IMPACT® powered with SOPHiA DDM™. 

• The benefits of matched tumor-normal sequencing in distinguishing somatic vs. germline variants.